Table 5.
Statistical values for IHC data analysis.
| Dataset | Main effect | Interaction | Multiple comparisons | ||||
|---|---|---|---|---|---|---|---|
| F (DFn,DFd) | p-value | F (DFn,DFd) | p-value | Effect | Groups | p-value | |
| Male mice ATF3+ cells | Treatment: F (1, 8) = 10.67 | 0.0114 | F (1, 8) = 2.042 | 0.1909 | Treatment | Vehicle | 0.6539 |
| Paclitaxel | 0.4838 | ||||||
| Genotype: F (1, 8) = 0.04 | 0.8434 | Genotype | WT | 0.4073 | |||
| eIF4ES209A | 0.0210 | ||||||
| Female mice ATF3+ cells | Treatment: F (1, 8) = 8.067 | 0.0218 | F (1, 8) = 0.600 | 0.4609 | Treatment | Vehicle | 0.9803 |
| Paclitaxel | 0.4179 | ||||||
| Genotype: F (1, 8) = 1.067 | 0.3319 | Genotype | WT | 0.0666 | |||
| eIF4ES209A | 0.3313 | ||||||
| Male mice Iba1 | Treatment: F (1, 8) = 10.06 | 0.0132 | F (1, 8) = 6.556 | 0.0336 | Treatment | Vehicle | >0.9999 |
| Paclitaxel | 0.0140 | ||||||
| Genotype: F (1, 8) = 13.24 | 0.0066 | Genotype | WT | 0.0220 | |||
| eIF4ES209A | >0.9999 | ||||||
| Female mice Iba1 | Treatment: F (1, 6) = 7.540 | 0.0335 | F (1, 6) = 18.22 | 0.0053 | Treatment | Vehicle | 0.9194 |
| Paclitaxel | 0.0029 | ||||||
| Genotype: F (1, 6) = 40.14 | 0.00071 | Genotype | WT | 0.0153 | |||
| eIF4ES209A | >0.9999 | ||||||
| Male mice GFAP | Treatment: F (1, 8) = 12.90 | 0.0071 | F (1, 8) = 7.104 | 0.0286 | Treatment | Vehicle | 0.0133 |
| Paclitaxel | >0.9999 | ||||||
| Genotype: F (1, 8) = 1.075 | 0.3301 | Genotype | WT | >0.9999 | |||
| eIF4ES209A | 0.1845 | ||||||
| Female mice GFAP | Treatment: F (1, 6) = 40.81 | 0.0007 | F (1, 6) = 0.1627 | 0.7007 | Treatment | Vehicle | 0.0180 |
| Paclitaxel | 0.0329 | ||||||
| Genotype: F (1, 6) = 2.078 | 0.1995 | Genotype | WT | >0.9999 | |||
| eIF4ES209A | >0.9999 | ||||||
Two-way ANOVA was performed followed by Sidak’s post-hoc for ATF3+ cell number and Bonferroni’s post-hoc for Iba1 and GFAP for multiple comparisons between genotypes and treatments for each sex. p ≤ 0.05 was considered significant (bolded).